Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00095225 |
This Phase II, multicenter, randomized trial is designed to make preliminary evaluations of the efficacy of combining bevacizumab with chemotherapy (docetaxel or pemetrexed) or Tarceva relative to chemotherapy (docetaxel or pemetrexed) alone in patients with previously treated advanced NSCLC.
Condition | Intervention | Phase |
---|---|---|
Non-Small-Cell Lung Carcinoma Neoplasm Recurrence, Local |
Drug: Avastin (bevacizumab) Drug: Tarceva (erlotinib HCl) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell Lung Cancer |
Enrollment: | 122 |
Study Start Date: | July 2004 |
Study Completion Date: | November 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Vince O'Neill, M.D. | Genentech |
Study ID Numbers: | OSI2950g |
Study First Received: | November 1, 2004 |
Last Updated: | January 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00095225 |
Health Authority: | United States: Food and Drug Administration |
Recurrent or refractory non-small cell lung cancer |
Erlotinib Thoracic Neoplasms Non-small cell lung cancer Bevacizumab Recurrence Carcinoma Docetaxel |
Pemetrexed Respiratory Tract Diseases Lung Neoplasms Lung Diseases Neoplasm Recurrence, Local Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |
Respiratory Tract Neoplasms Disease Attributes Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors Protein Kinase Inhibitors |
Angiogenesis Inhibitors Pharmacologic Actions Neoplasms Neoplastic Processes Neoplasms by Site Pathologic Processes Therapeutic Uses Angiogenesis Modulating Agents Growth Inhibitors |